The company was founded in 2004, headquartered in Ningbo City, Zhejiang Province, and listed on the main board of the Shanghai Stock Exchange on April 7, 2017. The company is a comprehensive international pharmaceutical technology manufacturing enterprise specializing in R&D, production and sales of specialty APIs (including intermediates) and finished drugs. It is one of the enterprises that exports the most types of specialty ingredients to Europe domestically, and has been ranked as one of the “Top 20 Chinese CDMO Companies” for many years. The company is a comprehensive international pharmaceutical technology manufacturing enterprise specializing in R&D, production and sales of specialty APIs (including intermediates, the same below) and formulations. The company's main products are perindopril tert-butylamine tablets, pregabalin capsules, atorvastatin calcium tablets, losartan potassium tablets, glizide sustained-release tablets, olmesartan ester tablets, moxifloxacin hydrochloride tablets, and apixaban tablets. Corporate honors: Provincial and municipal honest private enterprises, Minovar brand trademarks won the “Ningbo Famous Trademark”, provincial and municipal technology-based enterprises, demonstration units for corporate culture construction, etc.